Louisiana State Employees Retirement System Purchases New Holdings in Enovis Co. (NYSE:ENOV)

Louisiana State Employees Retirement System purchased a new stake in Enovis Co. (NYSE:ENOV) during the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 14,000 shares of the company’s stock, valued at approximately $784,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ENOV. Fifth Third Bancorp lifted its stake in Enovis by 144.6% in the 3rd quarter. Fifth Third Bancorp now owns 587 shares of the company’s stock valued at $31,000 after buying an additional 347 shares in the last quarter. UMB Bank n.a. purchased a new position in Enovis in the 3rd quarter worth approximately $31,000. First Horizon Advisors Inc. lifted its stake in Enovis by 902.7% in the 3rd quarter. First Horizon Advisors Inc. now owns 732 shares of the company’s stock worth $39,000 after purchasing an additional 659 shares in the last quarter. Annis Gardner Whiting Capital Advisors LLC purchased a new position in Enovis in the 3rd quarter worth approximately $82,000. Finally, Mitsubishi UFJ Trust & Banking Corp purchased a new position in Enovis in the 3rd quarter worth approximately $101,000. 98.45% of the stock is owned by hedge funds and other institutional investors.

Enovis Stock Up 0.2 %

Shares of NYSE ENOV opened at $55.23 on Friday. The company has a 50 day simple moving average of $59.95 and a 200-day simple moving average of $55.48. The company has a market capitalization of $3.03 billion, a P/E ratio of -90.54 and a beta of 1.97. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.43 and a quick ratio of 1.16. Enovis Co. has a 1 year low of $43.04 and a 1 year high of $66.14.

Enovis (NYSE:ENOV) last posted its earnings results on Thursday, February 22nd. The company reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.76 by $0.03. Enovis had a negative net margin of 1.95% and a positive return on equity of 3.84%. The firm had revenue of $455.00 million during the quarter, compared to the consensus estimate of $444.34 million. During the same quarter last year, the firm earned $0.72 EPS. The firm’s revenue for the quarter was up 11.2% on a year-over-year basis. On average, equities research analysts predict that Enovis Co. will post 2.58 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on ENOV shares. Wells Fargo & Company raised their target price on shares of Enovis from $73.00 to $79.00 and gave the stock an “overweight” rating in a research note on Friday, February 23rd. Needham & Company LLC reissued a “buy” rating and issued a $82.00 target price on shares of Enovis in a research note on Wednesday, April 10th. UBS Group assumed coverage on shares of Enovis in a research note on Monday, January 22nd. They issued a “buy” rating and a $75.00 target price on the stock. Stephens assumed coverage on shares of Enovis in a report on Tuesday, February 13th. They set an “overweight” rating and a $72.00 price target for the company. Finally, Canaccord Genuity Group raised their price target on shares of Enovis from $73.00 to $75.00 and gave the stock a “buy” rating in a report on Friday, February 23rd. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Enovis presently has an average rating of “Buy” and a consensus price target of $75.43.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.